EchoIQ Limited (AU:EIQ) has released an update.
Echo IQ’s AI technology, EchoSolv, has demonstrated a significant improvement in identifying patients with severe aortic stenosis, surpassing human diagnosis by 15%, particularly in low-flow states. Presented by Dr. Pedro Covas at New York Valves Summit, this independent research underscores the potential for EchoSolv to enhance diagnostic rates in cardiology. With FDA clearance anticipated shortly, Echo IQ anticipates rapid commercial adoption of its AI solution.
For further insights into AU:EIQ stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
